Cognex®
Cognex® 30 Capsules used for
States related to age, cognitive impairment and memory.
Cognex® 30 Capsules
Cognitive functions are mental processes that allow us to perform any task. They include the ability to think, concentrate, pay attention, memorize, transform, elaborate and retrieve information to function properly.
Cognitive function can begin to deteriorate naturally around of 50s. To help protect cognitive functions, it is necessary to maintain a healthy lifestyle (diet, exercise, reading, memory training, etc.) and modify habits and harmful lifestyles. The loss of oxidizing homeostasis leads to increased oxidative stress, this to cell death and thus to cognitive dysfunction in aging. Turmeric can help control oxidative stress and maintain nervous system function and mental balance.
Cognex® 30 capsules is a nutraceutical product based on Theracurmin®, a bioactive turmeric extract obtained through a specific formulation process, which improves its bioavailability to obtain its maximum benefits.
INFORMATION
Uses:
Cognex® by Laboratorios Farmolab is a food supplement that can provide a neuroprotective effect.
Certain pathologies associated with age are accompanied by a deterioration of cognitive functions, increasing neuroinflammation, and by an increased level of oxidative stress, causing cognitive deterioration, and/or dysfunction in memory and other cognitive functions.
In case of such pathologies, offering neuroprotection in order to minimise cognitive deterioration can be of great help.
Presentation:
NATIONAL CODE (C.N.): 197024.4
Box of 30 capsules.
Instructions for use:
It is recommended to take 1 or 2 Cognex® capsules per day with a glass of water.
A minimum of 12 months is recommended, although this product can be taken on an ongoing long-term basis.
It is suitable for gluten- and lactose-intolerant patients and diabetics.
Store in a cool and dry place, away from light, at a temperature less than 25° C. Avoid sudden changes in temperature. The expiration date is applicable to the product with the original packaging intact and properly stored. Keep out of reach of children under 3 years of age. Food supplements are not intended to replace a varied and balanced diet and a healthy lifestyle. Do not exceed the suggested daily dose. Do not take in case of hypersensitivity to one or more components of this product.
Composition
Theracurmin® 60mg
Is a Submicron Colloidal Dispersion Particles of Curcuminoids and Curcuminoids. Characterised by a very high level of absorbency and bioavailability, allowing it to cross the BBB and to reach the CNS.
Adapted from Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo Controlled 18-Month Trial. Small et al. Am J Geriatr Psychiatry. 2018 Mar;26(3):266-277.
BIBLIOGRAPHY
Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem., 280, 5892–5901 (2005).Ono, K., Hasegawa, K., Naiki, H., Yamada, M., 2004. Curcumin has potent anti-amyloidogenic effects for Alzheimer’s -amyloid fibrils in vitro. J. Neurosci. Res. 750, 742–750. Kulkarni SK, Bhutanio. Gary W. Small, M.D., Prabha Siddarth, Ph.D., Zhaoping Li, M.D., Ph.D., Karen J. Miller, Ph.D., Linda Ercoli, Ph.D., Natacha D. Emerson, M.A., Jacqueline Martinez, M.B.A., M.S., Koon-Pong Wong, Ph.D., Jie Liu, Ph.D., David A. Merrill, M.D., Ph.D., Stephen T. Chen, M.D., Susanne M. Henning, Ph.D., R.D., Nagichettiar Satyamurthy, Ph.D., Sung-Cheng Huang, D.Sc., David Heber, M.D., Ph.D., Jorge R. Barrio, Ph.D. Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial.Am J Geriatr Psychiatry 26:3,March 2018. Jihyun Kim, Jaehoon Kim, Zhouchi Huang, Nayeon Goo, Ho Jung Bae, Yongwoo Jeong, Ho Jae Park, Mudan Cai, Kyungnam Cho, Seo Yun Jung, Soo Kyung Bae and Jong Hoon Ryu. Theracurmin Ameliorates Cognitive Dysfunctions in 5XFAD Mice by Improving Synaptic Function and Mitigating Oxidative Stress. Biomol Ther 27(3), 327-335 (2019). Gary W. Small, M.D., Vladimir Kepe, Ph.D., Linda M. Ercoli, Ph.D., Prabha Siddarth, Ph.D., Susan Y. Bookheimer, Ph.D., Karen J. Miller, Ph.D., Helen Lavretsky, M.D., Alison C. Burggren, Ph.D., Greg M. Cole, Ph.D., Harry V. Vinters, M.D., Paul M. Thompson, Ph.D., S.-C. Huang, Ph.D., N. Satyamurthy, Ph.D., Michael E. Phelps, Ph.D., and Jorge R. Barrio, Ph.D. PET of Brain Amyloid and Tau in Mild Cognitive Impairment. N Engl J Med 2006;355:2652-63. Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katanasaka Y, Kakeya H, Fujita M, Hasegawa K, Morimoto T. Innovative preparation of curcumin for improved oral bioavailability. Biol. Pharm. Bull., 34, 660–665 (2011). 23). Sunagawa Y, Hirano S, Katanasaka Y, Miyazaki Y, Funamoto M, Okamura N, Hojo Y, Suzuki H, Doi O, Yokoji T, Morimoto E, Takahashi T, Ozawa H, Imaizumi A, Ueno M, Kakeya H, Shimatsu A, Wada H, Hasegawa K, Morimoto T. Colloidal submicron-particle curcumin exhibits high absorption efficiency—a double-blind, 3-way crossover study. J. Nutr. Sci. Vitaminol., 61, 37–44 (2015). Kanai M, Otsuka Y, Otsuka K, Sato M, Nishimura T, Mori Y, Kawaguchi M, Hatano E, Kodama Y, Matsumoto S, Murakami Y, Imaizumi A, Chiba T, Nishihira J, Shibata H. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother. Pharmacol., 71, 1521–1530 (2013). Takahashi M, Suzuki K, Kim HK, Otsuka Y, Imaizumi A, Miyashita M, Sakamoto S. Effects of curcumin supplementation on exercise-induced oxidative stress in humans. Int. J. Sports Med., 35, 469–475 (2014). Imaizumi A. Highly bioavailable curcumin (Theracurmin): its development and clinical application. PharmaNutrition, 3, 123–130 (2015). Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res., 67, 3853–3861 1524 (2007). Small G. Oral Presentation at the American Society for Nutrition. Boston MA 2018. Erken N., et al. The Effect of Theracurmin on Cognitive Function in an Older Patient with Chemobrain. Clinical Interventions in Aging 2020:15 691-693. Noel Torres-Acosta, James H., O’Keefe, Evan L. O’Keefe, Richard Isaacson and Gary Small. Therapeutic Potential of TNF- Inhibition for Alzheimer’s Disease Prevention. Journal of Alzheimer’s Disease, vol. Pre-press, no. Pre-press, pp. 1-8, 2020. DOI:10.3233/JAD-200711.